US Finalizes Anti-Dumping and Subsidy Duties on Indian Oleoresin Paprika Exports

On September 18, 2026, the US International Trade Commission (USITC) voted 5-0 to confirm that imports of oleoresin paprika from India are injuring US producers, clearing the way for formal anti-dumping and countervailing duty orders to take effect. The case has moved through a full year-long investigation process, and it offers a useful real-world example of how trade-remedy cases unfold for Indian agri-commodity exporters, even those who never touch the specific product involved.

What the US Decided, and What the Numbers Say

The investigation covered oleoresin paprika and paprika extract, the concentrated colour-and-flavour compound processed from chillies, used mainly in food colouring and seasoning blends. On August 18, 2026, the US Department of Commerce issued its final determinations in the parallel cases (A-533-938 and C-533-939), setting weighted-average anti-dumping margins of 5.78% for Synthite Industries Pvt. Ltd., 4.24% for Mane Kancor Ingredients Private Ltd., and 5.08% for all other Indian exporters not individually examined. Alongside this, Commerce set countervailing (subsidy) duty rates of 25.42% for Synthite, 18.67% for Mane Kancor, and 21.90% for all other Indian producers, after finding the companies benefited from government subsidy programmes. The case originated from a petition filed by a US producer, Rezolex, Ltd. Co. of Las Cruces, New Mexico. Import data cited in Commerce's own filings show US imports of the relevant HTSUS-classified products from India were valued at roughly $56.4 million in 2024, down from about $68 million in 2022 — though Commerce itself cautions that these broader tariff-code figures include non-subject merchandise alongside the paprika extract actually under investigation.

Why This Matters Beyond Paprika Extract

Oleoresin paprika is a narrow product line, but the case illustrates two things every Indian spice exporter dealing with the US market should keep in mind. First, US trade-remedy investigations into Indian agri-processed goods run on a predictable, multi-stage timeline — preliminary CVD determination, preliminary AD determination, final determinations from Commerce, and then a final injury vote from the USITC roughly a month later — and each stage is publicly tracked on trade.gov and usitc.gov. Second, once the USITC's injury vote is affirmative, as it was here, the path to formal duty orders being published in the Federal Register is largely procedural, meaning the real window for exporters to position pricing, sourcing or alternative markets is during the investigation itself, not after. The USITC's detailed public report on the case, Publication 5794, is due out by October 29, 2026.

Business Takeaway

For Indian chilli and spice exporters, the lesson is less about this one product and more about watch-and-prepare discipline: when a US trade-remedy petition is filed against any Indian spice-adjacent product, it is worth tracking the case through Commerce's preliminary and final determinations rather than waiting for the outcome to be final news. Exporters supplying chilli powder and other chilli-derived products to international buyers should factor in that the US market, in particular, has an active trade-remedy environment for chilli-based imports right now, and should discuss with buyers and freight partners how duty classification and country-of-origin documentation are being handled on their own shipments.